[junkie-button url=”https://infomeddnews.com/” style=”grey” size=”medium” type=”round” target=”_blank”] HOME [/junkie-button]
Per Elixir Medical, DynamX, a 71 microns thin cobalt-chromium DES coated with a thin, biodegradable polymer coating that releases Novolimus, an anti-proliferative and anti-inflammatory, is the first of its kind in its ability to allow the vessel to resume arterial pulsatile motion and the Glagovian phenomenon of adaptive remodeling which are both essential for slowing disease progression and minimizing clinical events. Adaptive segments in the stent are held intact by the thin biodegradable polymer coating designed to absorb in six months allowing the adaptive segments to uncage the stent and restore the natural pulsatile motion and adaptive remodeling of the artery.
Current DES permanently cages the artery, causing geometric distortion and stresses that contribute to fractures in approximately 20% of stents implanted leading to clinical events. DynamX demonstrated significantly improved conformability, and reduced torsional and longitudinal stresses compared to current DES, thereby reducing geometric distortion of arteries and the potential for stent fractures and clinical events.
Elixir unveiled DynamX at a packed evening symposium on Monday attended by cardiologists from around the world and industry professionals. The first clinical experience with DynamX was also presented during the Elixir Medical Evening Symposium by Professor Stefan Verheye, M.D., PhD.
Stefan Verheye, M.D., Ph.D., Antwerp, Belgium said, “The acute performance of DynamX matched the best in class DES,” said Professor Stefan Verheye, M.D., Ph.D., Antwerp, Belgium. “I am very excited about the potential of DynamX leading PCI to the next frontier.”
Prof. Verheye presented DynamX’s clinical program overview at the TCT conference Monday night and was joined by a distinguished panel of faculty Co-Chairs: Dr. Martin Leon, Dr. Dean Kereiakes and Dr. Roxana Mehran.
In addition to launching a new genre of bioadaptive drug eluting stents with DynamX, Elixir also continues to make advances with its bioresorbable scaffold programs, DESolve CX and DESolve NXT. DESolve’s ability to degrade in six months and nearly completely resorb in one year, while demonstrating positive adaptive remodeling at six month follow-up have all been affirmations of their respective proprietary technologies and the promising future of the category.
“Elixir is committed to lead the industry to a new and exciting era with its bio-adaptive DynamX DES. Elixir is executing on a two-pronged strategy with BRS and BA-DES to develop innovative, adaptive remodeling technologies designed to restore the normal function of arteries,” concluded Motasim Sirhan, CEO of Elixir Medical Corporation